Department of Medicine, University of Chicago Pritzker School of Medicine, 5841 S. Maryland Ave, MC 6080, Chicago, IL 60637, USA.
Curr Atheroscler Rep. 2012 Feb;14(1):70-7. doi: 10.1007/s11883-011-0214-z.
Thiazide diuretics and beta-blockers are first-line therapies for hypertension unless there are compelling indications for other drug classes. Diuretics and beta-blockers, however, may worsen dyslipidemia and glucose tolerance whereas antihypertensive agents in other drug classes may have neutral or beneficial effects. Initial clinical trials of antihypertensive regimens suggested that blood pressure lowering was the most important aspect of therapy and that the adverse effects on lipids and glucose tolerance did not impact clinical outcomes. Newer trials, however, question this finding and implicate these pleotropic effects as contributing to the results of the trials. Patients with cardiometabolic risk factors may have compelling indications for agents that inhibit the renin-angiotensin-aldosterone system, relegating diuretics and beta-blockers to third-line therapy.
噻嗪类利尿剂和β受体阻滞剂是高血压的一线治疗药物,除非有其他药物类别的强烈适应证。然而,利尿剂和β受体阻滞剂可能会加重血脂异常和葡萄糖耐量,而其他药物类别的降压药物可能具有中性或有益的作用。最初的抗高血压治疗方案临床试验表明,降低血压是治疗的最重要方面,而对血脂和葡萄糖耐量的不良影响并不影响临床结果。然而,新的试验对这一发现提出了质疑,并暗示这些多效性作用是导致试验结果的原因之一。患有心脏代谢危险因素的患者可能有强烈的适应证需要使用抑制肾素-血管紧张素-醛固酮系统的药物,将利尿剂和β受体阻滞剂降级为三线治疗。